Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
(4) - EconoTimes)
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
